GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Moderate Buy" from Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fifteen analysts that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $8.38.

A number of equities research analysts have issued reports on the company. Mizuho started coverage on GoodRx in a research note on Wednesday, December 4th. They set a "neutral" rating and a $5.00 price target for the company. Morgan Stanley lowered their price objective on GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Tuesday, December 17th. Barclays dropped their price target on GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a research note on Monday, November 11th. Citigroup lowered their price target on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a report on Friday, January 10th. Finally, KeyCorp lowered their price objective on GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th.

GoodRx Stock Performance

Shares of GDRX stock traded up $0.07 on Thursday, reaching $4.42. The stock had a trading volume of 814,093 shares, compared to its average volume of 1,325,807. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. GoodRx has a 1 year low of $4.09 and a 1 year high of $9.26. The stock has a market cap of $1.68 billion, a P/E ratio of -147.33, a price-to-earnings-growth ratio of 2.30 and a beta of 1.27. The company has a 50 day simple moving average of $4.61 and a 200 day simple moving average of $6.49.

Institutional Investors Weigh In On GoodRx

Several hedge funds have recently modified their holdings of GDRX. nVerses Capital LLC bought a new stake in GoodRx during the third quarter valued at about $33,000. EP Wealth Advisors LLC purchased a new stake in GoodRx during the 3rd quarter worth approximately $73,000. Sanctuary Advisors LLC acquired a new position in GoodRx during the 3rd quarter valued at approximately $85,000. Dark Forest Capital Management LP purchased a new position in shares of GoodRx in the second quarter worth $86,000. Finally, Sugar Maple Asset Management LLC acquired a new stake in shares of GoodRx during the fourth quarter worth $122,000. Hedge funds and other institutional investors own 63.77% of the company's stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.